Ekiz_2018_Arch.Pharm.(Weinheim)__e1800167

Reference

Title : Synthesis, characterization, and SAR of arylated indenoquinoline-based cholinesterase and carbonic anhydrase inhibitors - Ekiz_2018_Arch.Pharm.(Weinheim)__e1800167
Author(s) : Ekiz M , Tutar A , Okten S , Butun B , Kocyigit UM , Taslimi P , Topcu G
Ref : Arch Pharm (Weinheim) , :e1800167 , 2018
Abstract :

We report the synthesis of bromoindenoquinolines (15a-f) by Friedlander reactions in low yields (13-50%) and the conversion of the corresponding phenyl-substituted indenoquinoline derivatives 16-21 in high yields (80-96%) by Suzuki coupling reactions. To explore the structure-activity relationship (SAR), their inhibition potentials to inhibit acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and human carbonic anhydrase cyctosolic (hCA I and II) enzymes were determined. Monophenyl (16-18) indenoquinolines significantly inhibited the AChE and BChE enzymes in ranges of IC50 37-57 nM and 84-93 nM, respectively, compared with their starting materials 15a-c and reference compounds (galanthamine and tacrine). On the other hand, these novel arylated indenoquinoline-based derivatives were effective inhibitors of the BChE, hCA I and II, BChE and AChE enzymes with Ki values in the range of 37 +/- 2.04 to 88640 +/- 1990 nM for AChE, 120.94 +/- 37.06 to 1150.95 +/- 304.48 nM for hCA I, 267.58 +/- 98.05 to 1568.16 +/- 438.67 nM for hCA II, and 84 +/- 3.86 to 144120 +/- 2910 nM for BChE. As a result, monophenyl indenoquinolines 16-18 may have promising anti-Alzheimer drug potential and 3,8-dibromoindenoquinoline amine (15f) can be novel hCA I and hCA II enzyme inhibitors.

PubMedSearch : Ekiz_2018_Arch.Pharm.(Weinheim)__e1800167
PubMedID: 30079554

Related information

Citations formats

Ekiz M, Tutar A, Okten S, Butun B, Kocyigit UM, Taslimi P, Topcu G (2018)
Synthesis, characterization, and SAR of arylated indenoquinoline-based cholinesterase and carbonic anhydrase inhibitors
Arch Pharm (Weinheim) :e1800167

Ekiz M, Tutar A, Okten S, Butun B, Kocyigit UM, Taslimi P, Topcu G (2018)
Arch Pharm (Weinheim) :e1800167